Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences Inc. (Nasdaq: KOD) announced on Oct. 5, 2020, that it has treated the first patients in pivotal Phase 3 studies for KSI-301, an anti-VEGF therapy targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). The studies, GLEAM and GLIMMER, focus on treatment-naïve DME patients, while BEACON targets RVO patients. The ongoing DAZZLE study for wet AMD has completed U.S. recruitment. Initial Phase 1b results indicate that KSI-301 demonstrates significant durability with high treatment-free intervals. Kodiak aims to submit a BLA for KSI-301 by 2022.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical firm focused on retinal diseases, will present at two virtual investor conferences: the Citi 15th Annual BioPharma Conference on September 10 at 9:35 a.m. PT and the Morgan Stanley 18th Annual Global Healthcare Conference on September 17 at 10:15 a.m. PT. Webcasts of these presentations will be available on Kodiak's website, along with a limited-time replay option. Kodiak is advancing therapies aimed at preventing blindness caused by retinal conditions using its proprietary ABC Platform™.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q2 2020 results, highlighting significant advancements in their KSI-301 program targeting retinal diseases. CEO Victor Perlroth noted robust enrollment in the DAZZLE study for wet AMD, with 375 patients enrolled as of July 30, 2020. The company has a strong cash position of $417.1 million, but reported a net loss of $26 million. Increased R&D expenses of $20.6 million reflect ongoing clinical development. Kodiak remains on track for pivotal study initiations in 2020 and aims for a BLA submission in 2022.
Kodiak Sciences Inc. (Nasdaq: KOD) announced an R&D webcast on July 27, 2020, to discuss safety, efficacy, and durability data from its ongoing Phase 1b study of KSI-301 in treating retinal diseases like wet AMD, DME, and RVO. Management will review progress on the pivotal DAZZLE study in treatment-naïve wet AMD patients and planned pivotal studies for other conditions. KSI-301 aims to improve treatment outcomes and prevent vision loss in these diseases.
Kodiak Sciences (Nasdaq: KOD) announced positive data from its Phase 1b study of KSI-301, an anti-VEGF therapy for retinal diseases. Over 100 patient-years of data confirm KSI-301's safety and efficacy, with 82% of wet AMD and 76% of DME patients remaining treatment-free for four months post-initial doses. The therapy showed limited intraocular inflammation with significant vision improvements. Kodiak plans further pivotal studies in DME, RVO, and diabetic retinopathy, targeting a BLA submission by 2022, underpinned by strong clinical support and community engagement.
Kodiak Sciences Inc. (Nasdaq: KOD) announced that new data from the ongoing Phase 1b study of KSI-301, a novel anti-VEGF antibody biopolymer conjugate, will be presented at the ASRS 2020 Virtual Annual Meeting. The presentation will take place on July 10, 2020, showcasing results from 121 patients with wet AMD, diabetic macular edema, and retinal vein occlusion. CEO Victor Perlroth highlighted the promising safety and efficacy data accumulated across over 150 patient-years. A related R&D webinar is set for July 27, 2020, to discuss the implications of these findings.